[1] Sartiani L, Bettiol E, Stillitano F, et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach [J].
Stem Cells, 2007, 25(5): 1136-1144.
[2] Mummery C, Van Der Heyden M A, De Boer T P, et al. Cardiomyocytes from human and mouse embryonic stem cells [J]. Methods in Molecular Medicine, 2007, 140: 249-272.
[3] Mummery C. Cardiomyocytes from human embryonic stem cells: more than heart repair alone [J]. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology,
2007, 29(6): 572-579.
[4] Wendel J S, Ye L, Tao R, et al. Functional effects of a tissue-engineered cardiac patch from human induced pluripotent stem cell-derived cardiomyocytes in a rat infarct
model [J]. Stem Cells Translational Medicine, 2015, 4(11): 1324-1332.
[5] Pekkanen-Mattila M, Chapman H, Kerkela E, et al. Human embryonic stem cell-derived cardiomyocytes: demonstration of a portion of cardiac cells with fairly mature electrical phenotype[J]. Experimental Biology and Medicine, 2010, 235(4): 522-530.
[6] Zhang J, Wilson G F, Soerens A G, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells [J]. Circulation Research, 2009, 104(4): e30-e41.
[7] Chan H Y, Cheung M C, Gao Y, et al. Expression and reconstitution of the bioluminescent Ca(2+) reporter aequorin in human embryonic stem cells, and exploration of the presence
of functional IP3 and ryanodine receptors during the early stages of their differentiation into cardiomyocytes [J]. Science China Life Sciences, 2016, 59(8): 811-824.
[8] Binah O, Dolnikov K, Sadan O, et al. Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes [J]. Journal of Electrocardiology, 2007, 40: S192-
S196.
[9] Steel D, Hyllner J, Sartipy P. Cardiomyocytes derived from human embryonic stem cellscharacteristics and utility for drug discovery [J]. Current Opinion in Drug Discovery & Development, 2009, 12(1): 133-140.
[10] Rathjen P D, Lake J, Whyatt L M, et al. Properties and uses of embryonic stem cells: prospects for application to human biology and gene therapy [J]. Reproduction, Fertility, and Development, 1998, 10(1): 31-47.
[11] Adler S, Lindqvist J, Uddenberg K, et al. Testing potential developmental toxicants with a cytotoxicity assay based on human embryonic stem cells [J]. Alternatives to Laboratory Animals, 2008, 36(2): 129-140.
[12] Rovida C, Vivier M, Garthoff B, et al. ESNATS conference—the use of human embryonic stem cells for novel toxicity testing approaches [J]. Alternatives to Laboratory Animals, 2014,
42(2): 97-113.
[13] Genschow E, Spielmann H, Scholz G, et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods [J]. Alternatives to Laboratory Animals, 2002, 30(2): 151-176.
[14] Muller M, Fleischmann B K, Selbert S, et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro [J]. Faseb Journal, 2000, 14(15): 2540-2548.
[15] Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications [J]. Stem Cell Reviews, 2010, 6(1): 108-120.
[16] Xu C, Police S, Hassanipour M, et al. Efficient generation and cryopreservation of cardiomyocytes derived from human embryonic stem cells [J]. Regenerative Medicine, 2011,
6(1): 53-66.
[17] Arbel G, Caspi O, Huber I, et al. Methods for human embryonic stem cells derived cardiomyocytes cultivation, genetic manipulation, and transplantation [J]. Methods in Molecular
Biology, 2010, 660: 85-95.